Home › Funds › a16z Capital Management, L.L.C. › SYRE
a16z Capital Management, L.L.C. position in SYRE
SPYRE THERAPEUTICS INC · Health Care
a16z Capital Management, L.L.C. reported holding 3,082,725 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$56.7M, representing 0.29% of its reported portfolio and ranking #6 among its reported holdings. a16z Capital Management, L.L.C. first reported this position in Q3 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How a16z Capital Management, L.L.C.'s SYRE position evolved
a16z Capital Management, L.L.C. first disclosed a stake in SYRE in Q3 2026 at 3,082,725 shares (US$56.7M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 3.08M | $56.74M | New |
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 68 other funds we track also report a position in SYRE — the largest reported positions include Paradigm Biocapital Advisors LP (US$396.8M), RTW INVESTMENTS, LP (US$328.7M), PERCEPTIVE ADVISORS LLC (US$309.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- Paradigm Biocapital Advisors LP 4.46M sh · $396.85M · Q3 2026
- RTW INVESTMENTS, LP 3.69M sh · $328.68M · Q3 2026
- PERCEPTIVE ADVISORS LLC 4.20M sh · $309.04M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.76M sh · $245.76M · Q3 2026
- Venrock Adviser, LLC 2.49M sh · $221.28M · Q3 2026
- TCG Crossover Management, LLC 1.90M sh · $169.21M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $168.46M · Q3 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.88M · Q3 2026
- Remedium Capital Partners, LLC 1.16M sh · $103.33M · Q3 2026
- Siren, L.L.C. 868.60K sh · $77.33M · Q3 2026
- BRAIDWELL LP 713.96K sh · $63.56M · Q3 2026
- Commodore Capital LP 700.00K sh · $62.32M · Q3 2026
More on a16z Capital Management, L.L.C.
FAQ
How long has a16z Capital Management, L.L.C. held SYRE?
a16z Capital Management, L.L.C. has disclosed SYRE holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is a16z Capital Management, L.L.C.'s current position in SYRE?
As of Q3 2026, a16z Capital Management, L.L.C. holds 3.08M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $56.74M, representing 0.29% of its reported portfolio and ranking #6.
Has a16z Capital Management, L.L.C. been buying or selling SYRE?
In the latest 13F filing (Q3 2026), a16z Capital Management, L.L.C. newly opened its position in SYRE.
Which other funds hold SYRE?
Other major institutional holders of SYRE include Paradigm Biocapital Advisors LP, RTW INVESTMENTS, LP, PERCEPTIVE ADVISORS LLC, among 68 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.